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peroxisome proliferator-activated receptors (PPARs) are nuclear receptors acting as lipid sensors. Besides its metabolic activity
in peripheral organs, the PPAR beta/delta isotype is highly expressed in the brain and its deletion in mice induces a brain
developmental defect. Nevertheless, exploration of PPARβ action in the central nervous system remains sketchy. The lipid content
alteration observed in PPARβ null brains and the positive action of PPARβ agonists on oligodendrocyte diﬀerentiation, a process
characterized by lipid accumulation, suggest that PPARβ acts on the fatty acids and/or cholesterol metabolisms in the brain. PPARβ
could also regulate central inflammation and antioxidant mechanisms in the damaged brain. Even if not fully understood, the
neuroprotective eﬀect of PPARβ agonists highlights their potential benefit to treat various acute or chronic neurological disorders.
In this perspective, we need to better understand the basic function of PPARβ in the brain. This review proposes diﬀerent leads for
future researches.
Copyright © 2008 M. G. Hall et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Nuclear receptors (NRs) represent the largest family of
transcription factors [1]. Up to today, 48 nuclear receptors
have been described in humans and 49 in mice [2].
Most of them are ligand-dependent receptors; their specific
ligands correspond to a diversity of hormones, steroids,
fat-soluble vitamins, fatty acids, oxysterols, bile acids, and
dietary lipids [3]. This broad range of ligand diversity
and capacity to regulate gene expression makes the NRs
key regulators of many pathways involved in reproduction,
metabolism, and development. The central nervous system
(CNS) expresses nearly all the NRs [2], but for most of
them we are still missing in-depth knowledge of their role
in brain development, cognition, behavior, and neurological
or psychiatric disorders [4]. Among the NR superfamily, the
peroxisome proliferator-activated receptors (PPARs), which
are described as lipid sensors, are the focus of intense interest,
particularly in the context of metabolic disorders and the
associated search for new therapies. Amazingly, in addition
to its metabolic activity in peripheral organs [5], the PPAR
beta/delta isotype is highly expressed in the brain [6] and
its deletion in mice is associated with a brain developmental
defect [7].
In vertebrates, the PPAR family is composed of three
diﬀerent isotypes. They are known as PPARα (NR1C1),
PPARβ (NR1C2) also named PPARδ , and PPARγ (NR1C3)
[8, 9]. PPARs regulate whole body metabolism in response
to dietary lipid intake, by directing their subsequent
metabolism and storage. Among their endogenous ligands
are poly-unsaturated fatty acids and lipid derivatives such as
eicosanoids. However, the search for specific ligands interact-
ing with the three individual receptors of the family has been
diﬃcult, owing to their relatively low aﬃnity interactions and
broad ligand specificity. PPAR: retinoid-X-receptor (RXR)
heterodimers represent the functional entities and bind to
conserved regulatory DNA elements and termed peroxisome
proliferator response elements (PPREs). PPREs correspond
to a repetition of two hexamers, derived from the AGGTCA
consensus motif, separated by one nucleotide, and we still
understand little on the binding selectivity of the three
PPAR isotypes according to the nucleotide sequence of these
response elements. PPAR-mediated transcriptional activity
is a multistep process. In the absence of ligands, PPAR is
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associated with corepressors. Upon ligand binding, they
are replaced by coactivators, which recruit the basal tran-
scriptional machinery. Thus, PPAR transcriptional activity
is depending on a combination of ligand availability, RXR
expression, and numerous cofactor interactions. This com-
plexity together with a relatively specific tissue expression of
PPARα and PPARγ contributes to the selective PPAR isotype
activity.
PPARβ is an intriguing member of the PPAR family.
It presents a fairly ubiquitous expression pattern from
early embryonic up to adult stages. Its near-ubiquitous
expression raised early speculation that it may have a “general
housekeeping role” [10]. The phenotype of PPARβ-null mice
highlights its role in development. PPARβ deletion induces
a high rate of embryonic mortality around early embryonic
day 10.5 (E10.5) due to a placental defect [7, 11, 12]. The
phenotype of the surviving PPARβ-null mice is rather mild.
They present a reduction of adipose tissue [7], an altered
skin inflammatory response [7, 13], a decreased number of
Paneth cells in the intestine [14], some discrete metabolic
modification in muscle [7, 15], and impaired wound healing
[16]. PPARβ-null mice also present a myelin alteration [7]
but exploration of the PPARβ function in the brain remains
sketchy. In this review, we highlight the few known facts and
propose some hypotheses.
2. EVIDENCE FOR PPARβ ACTIVITY IN THE BRAIN
During development, PPARβ expression starts at mid-
gestation, around E10.5 days in rats, and then reaches a
peak in all neural tissue between E13.5 and E15.5 [17]. Even
though it then fades slightly, it remains high all through
development and adult life. In the adult brain, PPARβ is
expressed ubiquitously, with high levels found in the cerebral
cortex, thalamus, cerebellum, and brain stem [4, 18, 19]
(Figure 1).
Most brain cell types appear to express PPARβ. Immun-
ostaining, western blots, and RT-PCR confirmed their
expression in primary cultures of embryonic cortical neurons
[20]. Analyses of adult brain sections enabled more detailed
observations [21] revealing that pyramidal cells of the cere-
bral cortex, neurons of the hypothalamus, and accumbens
nuclei show high PPARβ expression. In situ hybridization
coupled to immunolocalization revealed PPARβ mRNA and
protein expression within the oligodendrocytes of the corpus
callosum [19, 22]. PPARβ is also expressed in primary
cultures of rat cortical and cerebral astrocytes, as well as in
mouse cortical astrocytes [23, 24], even if, in vivo, astrocytes
appear negative to PPARβ immunostaining, at least in the
hippocampal commissure [19, 22].
Thus, the expression of PPARβ is documented in the
three main neural cell types: neurons, astrocytes, and
oligodendrocytes, whereas we still have no information for
microglia cells. Interestingly, PPARβ mRNA is also expressed
in the rat brain capillary endothelial cells [25], suggesting
that it plays a role in the brain-blood barrier.
Concerning its cellular localization, PPARβ immunos-
taining is detected in the cytoplasm and neurites of some
neurons [21], raising the question of PPARβ nongenomic
eﬀects in these specific cells. However, its main localization
is nuclear, as revealed by its exclusive detection in the nuclear
fraction of whole brain protein extracts [26].
PPARβ expression pattern suggests that it is involved in
basic physiological functions in the brain. However, the brain
phenotype of PPARβ-null mice is poorly documented. In
one study, the authors noted that PPARβ-null mice brain
diameters are significantly smaller than in wild-type mice,
most likely due to their relatively smaller body size [7].
Histological examination revealed alterations in the extent
of myelination in the corpus callosum, more often in female
than in male mice (three of five females; two of seven males).
This defect is absent in other parts of the brain, including the
cerebellum and brain stem. The two main proteins playing a
role in myelin organization, myelin basic protein (MBP) and
proteolipid protein (PLP), are not diﬀerentially expressed in
the corpus callosum of PPARβ-null mice, despite a putative
PPRE in the PLP promoter [27].
Thus, the full functional exploration of PPARβ activity in
the brain remains to be performed. In the following sections,
we summarize and comment on studies that chart the first
leads in this domain.
3. PPARβ AND LIPIDMETABOLISM IN THE BRAIN
The best-known role of PPARβ, with possible consequences
on the whole organism, is to increase lipid oxidative
metabolism in muscles, in particular fatty acid peroxisomal-
β oxidation [28]. Along this line, long-term treatment of
obese animals with the PPARβ agonist GW501516 causes
significant weight loss accompanied by improvement of the
lipoprotein profiles and metabolic parameters [29, 30]. Inter-
estingly, the brain lipid content of PPARβ-null mice is altered
in females: they present a 24% and 17% increase in plas-
menylethanolamine and phosphatidylserine, respectively,
and a 9% decrease in the level of phosphatidylinositol when
compared to controls animals [31]. The altered phospholipid
composition in female PPARβ-null brains could result from
a defect in brain peroxisomal acyl-CoA utilization. If true,
this could explain the altered myelination observed in
PPARβ-null mice, as inactivation of peroxisomal β oxidation
function induces demyelination in human and mouse brain
[32]. The fact that a PPARβ selective agonist (L165041)
increases the expression of AcylCoA synthtase 2 (ASC2) in
rat brain cell cultures [33] supports a direct role of PPARβ
on brain lipid metabolism. ASC2 turns fatty acids into fatty
acyl-CoA, a modification required for their metabolism.
However, in unchallenged conditions, ASC2 expression is not
changed in the adult brains of PPARβ-null mice compared to
wild-type mice [7]. If confirmed, the modification of brain
lipid composition in PPARβ-null mice may have multiple
impacts, including a modification of membrane plasticity or
an alteration of pathways requiring lipid post-translational
modifications. For example, acylation is a common post-
translational modification of myelin proteins [34] such as
PLP, which is crucial for the stabilization of myelin sheets.
Another example is the processing of Shh, which undergoes
cholesterol addition and palmitoylation to contribute to
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Figure 1: Expression of PPARβ in the adult mouse brain. Quantitative and spatial expression of PPARβ in the mouse brain: (a) Quantitative
RT-PCR data, (b) Brain sagittal section. Moderated expression levels are in red and weak expression in blue. OA: olfactory areas, Cx: cerebral
cortex, CP: caudate putamen, Hi: hippocampus, Th: thalamus, Hy: hypothalamus, Arc: arcuate nucleus, Co: colliculus, BS: brain stem, Cb:
cerebellum. (MousePat: http://www-mci.u-strasbg.fr/mousepat/- consulted 8-08-2008).
forebrain patterning [35]. Finally, an alteration of the lipid
metabolism can directly perturb neural diﬀerentiation, as
discussed above.
Numerous recent papers have highlighted the role of
PPARβ in cholesterol metabolism [36–40]. Even though the
CNS accounts for only 2.1% of body weight, it contains 23%
of the sterols present in the whole body pool. In PPARβ-null
mice, the total cholesterol content of the brain is not changed
compared to that of wild-type mice [31]. Nevertheless, it
does not imply that brain cholesterol metabolism is not
impaired. Cholesterol in the CNS comes almost entirely
from in situ synthesis with little or no transfer from the
blood into the brain, whereas cholesterol can leave the
brain and pass into the general circulation in the form of
24-hydroxycholesterol. Inside the brain, a large amount of
the cholesterol turnover is between glial cells and neurons
during CNS development, but also occurs in the context
of neuronal repair and remodeling. This internal recycling
involves the cellular exchange of cholesterol through inter-
mediate binding to apolipoproteins E and A1. Interestingly,
alteration of the cholesterol balance across the whole body
may alter sterol recycling and apolipoprotein E expression
within CNS, thereby aﬀecting neuron and myelin integrity
[41]. Altogether, these observations are a strong incitement
to exploring whether PPARβ acts on the fatty acids and
cholesterol metabolisms in the brain.
4. PPARβ ANDNEURAL CELL FATE
In diﬀerent models, PPARβ has a prodiﬀerentiation activity,
observed for various cell types such astrophoblast giant
cells [12], adipocytes [42, 43], sebocytes, Paneth cells in the
intestine [14], and keratinocytes under normal and inflam-
matory conditions [13, 44]. There is now some evidence that
PPARβ favors neural cell diﬀerentiation (Figure 2). However,
observations vary according to the models investigated and
many questions must be further addressed.
Oligodendrocytes are the myelin-producing cells in
the CNS. The timing of oligodendrocyte diﬀerentiation
depends on an intrinsic clock in oligodendrocyte precursor
cells (OPC) that counts time or cell divisions and limits
precursor cell proliferation. The timing of oligodendrocyte
diﬀerentiation depends on hormonal signals such as thyroid
hormones, glucocorticoids, and retinoic acid, which bind
and activate their cognate nuclear receptor [48]. Two facts
suggest a role of PPARβ in OPC diﬀerentiation: first, the
strong expression of PPARβ in these cells [47], and second
the partial alteration of the corpus callosum myelination in
the brain of PPARβ-null mice [7]. Cell culture experiments
support this hypothesis. In primary glial cell cultures and
oligodendrocyte enriched cultures prepared from neonatal
mouse brains, diﬀerent PPARβ agonists accelerated OPC dif-
ferentiation within 24 hours [46]. These treatments induced
by two- to three-fold the number of oligodendrocytes with
processes and huge membrane sheets. They also increased
the expression of some diﬀerentiation markers, such as MBP
and PLP, at the mRNA and protein levels [46]. While this
prodiﬀerentiation activity remains to be further documented
in vivo, it suggests that PPARβ contributes to the dietary lipid
activity in accelerating myelinogenesis [49, 50].
At the present time, we have few clues for how PPARβ
acts on oligodendrocyte diﬀerentiation while not aﬀecting
oligodendrocyte precursor proliferation [46]. Oligoden-
drocytes synthesize myelin and thus are the major lipid
producing cells in the CNS. Interestingly, a majority of
the cells that are sensitive to PPARβ during their dif-
ferentiation (adipocytes, trophoblast giant cells, sebocytes,
and keratinocytes) are characterized by lipid accumulation
during diﬀerentiation. Indeed, disruption of PPARβ resulted
in an alteration of mouse adipose tissue development [7].
In 3T3-L1 and 3T3-F442A cell lines which replicate in
vitro adipocyte diﬀerentiation, PPARβ is one of the early
activated genes [51]. In contrast to this early implication
in adipocyte diﬀerentiation, PPARβ regulates the late stages
of sebaceous cell diﬀerentiation [52]. It is also the most
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Figure 2: PPARβ potential role in neural cell diﬀerentiation during development. PPARβ is expressed in the embryo and in the diﬀerentiating
cells of the CNS and plays important role for the maintenance and/or diﬀerentiation of neural stem cells (NSC). PPARβ maintains
NSC in an undiﬀerentiated proliferative status [45]. Once the NSC cells have started to diﬀerentiate, PPARβ could play a role in (1)
neuronal diﬀerentiation, inducing the morphological characteristics and the gene expression patterns of neuronal cells, (2) promoting the
oligodendrocyte precursor cells (OPC) diﬀerentiation [46], strongly expressing PPARβ [47], to mature oligodendrocytes [7]. In promoting
diﬀerentiation, PPARβ also influences cell cycle and proliferation rate. Up to today no role has been clearly established for PPARβ in astrocyte
diﬀerentiation. (↑ Activation in red, ⊥ Repression in blue).
eﬀective PPAR isotype in stimulating lipid accumulation in
keratinocytes [53]. Finally, the diﬀerentiation of giant cells
in mouse placenta is accompanied by a PPARβ-dependent
accumulation of lipid droplets and an increased expression of
the adipose diﬀerentiation-related protein (ADRP, also called
adipophilin), which may participate in lipid metabolism
and/or steroidogenesis [12]. While the specificity of each
of these contexts suggests that PPARβ acts on diﬀerent
programs of diﬀerentiation [54], this contribution of PPARβ
to lipid synthesis may well also apply in oligodendrocytes,
accelerating their diﬀerentiation from precursor to fully
mature cells.
PPARβ action on neuronal diﬀerentiation is still under
investigation. In primary cultures of embryonic cortical
neurons, PPARβ is expressed in the neuron nuclei and
increases in relation to the degree of maturation of these
cells, in correlation with its heterodimer partners RXR β
and γ. The concomitant induction of the PPARβ target gene
ACS2 suggests that PPARβ is activated [20]. With respect
to neuronal diﬀerentiation per se, the available data are
limited to human neuroblastoma cell lines. Exposure of these
PPARβ expressing cells to PPARβ agonists, either oleic acid
or the GW610742X, triggers neuronal diﬀerentiation [20],
characterized by neuritis outgrowth. Both compounds also
promote morphological modifications of the actin filaments
[55] and induce the expression of a series of neuronal
diﬀerentiation markers such as growth associated protein
43 (GAP-43), neural cell adhesion molecule (N-CAM), and
neurofilament-200 [55]. As the cells undergo diﬀerentiation,
their proliferation rate, cellular migration, and invasiveness
are slowed down by oleic acid or GW610742X treatments. In
parallel, oleic acid or the GW610742X agonist increases the
expression of the cyclin inhibitor p16, indicating that PPARβ
activation may be able to promote cell cycle arrest [55]. All
GW610742X eﬀects are related to PPARβ, as demonstrated
by the use of siRNA silencing. In contrast, the oleic acid
eﬀects were never fully reverted thereby indicating that they
are only partially mediated by PPARβ.
These observations however need to be confirmed in
more physiological models, such as primary cultures of
neurons and mouse models. In fact, they contrast with
other data suggesting that PPARβ rather maintains neural
stem cells in an undiﬀerentiated, proliferative status [56].
In the model of neurospheres cultures, prepared from the
periventricular tissue of the adult mouse brain, western-blot
and RT-PCR analysis demonstrated that PPARβ is expressed
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in undiﬀerentiated neurospheres (S0) and decreases in
diﬀerentiated neurospheres (S10) [45]. In line with this, the
expression of PPARβ in primary cultures of mouse cortical
astrocytes also decreases between 14 and 21 divisions,
possibly in relation to the decreased astrocyte proliferation at
confluence [45]. In these studies, PPARβ activity correlates
with the expression of genes involved in cell cycle [20,
45, 57]. Nevertheless, PPARβ action on cell proliferation is
highly dependent on the cell type. For example, it exerts
a proproliferative action on preadipocytes [58, 59] and
an antiproliferative action on keratinocytes [60]. Moreover,
PPARβ proproliferative activity on neural stem cells does not
necessarily exclude a prodiﬀerentiation activity.
After this tour of the possible functions of PPARβ in
the brain, ranging from metabolism to neural cell fate, the
next sections of this review highlight the consequent roles of
PPARβ in brain alterations and repair.
5. PPARβ IN BRAIN ISCHEMIA
The role of PPARβ in brain repair was first addressed in
a model of focal cerebral ischemia, with a middle cerebral
artery occlusion. Compared with wild type, PPARβ-null
mice exhibited a significant increase in the infarct size
[61, 62], suggesting that PPARβ exerts a neuroprotective
activity. Intriguingly, the diﬀerence in infarct size between
wild-type and PPARβ-mutant mice was detected by RMN
as early as 30 minutes after performing the ischemia [62],
suggesting that PPARβ plays a role in the very early events.
Reciprocally, in a transient middle cerebral artery occlusion,
intracerebral infusion of L-165041 or GW501516 in rat
ventricle significantly attenuated the ischemic brain infarct
size 24 hours after reperfusion [63]. Several hypotheses
concerning the molecular mechanism of this neuroprotective
activity are discussed below.
An important activity of PPARβ is to promote cell
survival under stress conditions, as demonstrated in ker-
atinocytes during skin wound healing [50] and in primary
keratinocyte exposed to inflammatory signals [64]. PPARβ
activation also promotes renal cell survival following hyper-
tonic stress [65] as well as oxidative stress [66]. Neural cells
also seem to be sensitive to PPARβ activation under stress
conditions. In primary cultures of rat cerebellar granule
neurons, treatment with GW0742 significantly reduced
cell death during a 12-hour exposure to low-KCl media.
However, prolonged incubation (48 hours) with GW0742
produced significant inherent toxicity [67]. In a diﬀerent
context, human neuroblastoma SH-SY5Y cells were exposed
to a variety of chemicals provoking cell death, such as
thapsigarginand the endoplasmic reticulum calcium ATPase
inhibitor, 1-methyl-4-phenylpyridinium. Treatment with
two PPARβ agonists, L-165041 or GW501516, significantly
attenuated cell death in a concentration-dependent manner
[63]. In vivo, in a model of middle cerebral artery occlusion,
an increase of malondialdehyde and a decrease of glutathione
and manganese superoxide dismutase in PPARβ-null mice
argue for increased brain oxidative stress. This phenotype
was associated with a relative increase in interferon γ
but a lack of TNFα production [61]. Thus, PPARβ could
regulate central inflammation and antioxidant mechanisms
in the damaged brain. Some known PPARβ-regulated genes
could explain these observations, including COX2 [68],
which promotes inflammatory reactions by prostaglandins
synthesis [69]. Nevertheless, in vivo or in vitro treatment
of T cells with GW0742, a PPARβ selective agonist, did not
reduce IFNγ production [70]. Alternatively, PPARβ could
also act via the regulation of IL-1β to reduce astroglial and
microglial inflammatory activation, as suggested in experi-
mental autoimmune encephalomyelitis (EAE) [70]. PPARβ
inflammatory response could also involve a direct interaction
between PPARβ and the inflammatory suppressor protein,
BCL-6, as in macrophages [71].
While we can reasonably hypothesize that PPARβ may
indeed play a role in modulating inflammation and con-
trolling oxidative damages, thereby contributing to moderate
ischemia lesion, other hypotheses may also contribute to
understanding the increased ischemic lesion in PPARβ-null
mice. An interesting one concerns the role of PPARβ in
the vascular system. For example, a diﬀerent patterning of
vascular territories would result in a diﬀerent infarct size
occurring at the very first time point postischemia. An
experiment designed to visualize the vascular tree would then
provide an important control. Local conditions of blood flow
might also aﬀect the outcome of an ischemia experience.
However, no data so far have been published concerning
hemodynamic parameters in the brain of PPARβ-null mice.
Finally, angiogenesis itself might be concerned. This is
supported by investigations performed on an unrelated
model, using subcutaneous inoculation of lung carcinoma
cells carrying the two PPARβ wild-type alleles in a PPARβ-
null mutant mouse. In this model, the tumor growth was
impaired, due to the absence of PPARβ in the stroma cells
surrounding the developing tumor. This led to a diminished
blood flow and a reduced development of hyperplastic
microvascular structures [72]. Thus, PPARβ deletion could
also aﬀect the delayed response to ischemia by impairing
angiogenesis [73].
An interesting cellular property that may be overlooked
in the search for functional disturbances linking PPARβ
and cerebral ischemia is cell-cell adhesion and matrix-cell
adhesion. As proposed by del Zoppo et al. [74], matrix cell
adhesion receptors might be essential for the maintenance
of the integrity of the blood-brain permeability barrier,
challenged upon local injury. In particular, focal ischemia
suddenly alters the matrix constituents and changes the
expression of cell adhesion receptors, locally increasing
vascular permeability [75]. We summarize below some
indirect evidence for a role of PPARβ in cell adhesion, which
may contribute to its neuroprotective activity.
In an in vitro study, modulation of PPARβ activity in F9
teratocarcinoma cells positively correlated with modulation
of neural cell adhesion molecule (NCAM) expression. In fact,
F9 cells treated with valproic acid increased the expression
of PPARβ, but not that of PPARα or PPARγ, while also
enhancing the expression of cell adhesion molecules such
as NCAM and PST1. Reciprocally, overexpression of a
dominant-negative PPARβ reduced the NCAM induction
[76]. In endothelial cells of human umbilical, PPARβ
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directly regulated a few key cell-adhesion genes. PPARβ ago-
nists GW0742 and GW501516 significantly inhibited TNFα
induced expression of vascular cell adhesion molecule-1 and
E-selectin, and the ensuing endothelial-leukocyte adhesion
[77]. Chromatin immunoprecipitation assays showed that
GW0742 switched the interaction of BCL-6, a transcrip-
tion repressor, from PPARβ to the vascular cell adhesion
molecule-1 (VCAM-1) gene promoter. Evidence for a role of
PPARβ in cell adhesion/migration also stems from PPARβ
activity in wound healing, where it regulates the intracellular
pathways activated during keratinocyte directional sensing,
polarization, and migration [16]. In these events, redis-
tribution of integrins requires Akt1 activity while NF-κB
stimulates the production of the metalloproteinase MMP-9,
which allows the digestion of extracellular matrix, a process
required for cell migration. Since PPARβ concomitantly
regulates both Akt1 and NF-κB [64], it would be of great
interest to study these two pathways in the damaged brain.
In a more general way, cell adhesion is a key developmen-
tal process, as it determines the location of a cell by regulating
its capacity to move in a tissue or to be restricted to a
defined area. It is also crucial for neural cell-cell interactions,
including axon guidance and synapse formation, processes
tightly connected to the functioning of the brain itself, such
as learning and memory. Taking these observations together
points to the particular need for a better understanding of
PPARβ action on neural cell adhesion.
6. USING PPARβ AGONIST/ANTAGONIST TO
TREAT BRAIN DISEASES
Whereas many studies have explored the possible benefits
of targeting the ever popular PPARγ isotype with regard
to its neuroprotective eﬀect [78], an interest in the more
ubiquitous PPARβ isotype is recently emerging. In this last
section, we will therefore review studies that have explored
PPARβ targeted therapeutics for a variety of brain diseases.
Experimental autoimmune encephalomyelitis (EAE) [79,
80] is a T-cell mediated autoimmune disease that involves
inflammatory activation of brain glial cells, and is used as a
model for multiple sclerosis. Oral administration of PPARγ
agonists reduces the incidence and severity of clinical, his-
tological, and biochemical symptoms in EAE. The GW0742
PPARβ agonist has also beneficial eﬀects, demonstrated in a
mouse model of EAE, in which mice were immunized with
an encephalitogenic myelin oligodendrocyte glycoprotein
(MOG) peptide [70]. When given at the time of immuniza-
tion, GW0742 had only a moderate eﬀect on the appearance
and severity of clinical symptoms. Nevertheless, prolonged
treatment of mice already exhibiting signs of the disease
improved their clinical status. Intriguingly, the clinical
improvement of cortical lesions contrasts with no significant
reduction of the cerebellar lesions. The mechanism does
not involve T cell activation, oligodendrocyte maturation, or
survival, but probably a reduction of astrocyte and microglial
inflammatory responses [70]. Thus, PPARβ and PPARγ
agonists diﬀer both in the timing of treatment eﬃciency and
the molecular mechanism involved [81].
The absence of PPARβ agonist action on oligodendrocyte
maturation or survival in this model of EAE is surprising
(see Section 4). It is thus tempting to explore how the
PPARβ agonist could alter the course of a nonautoimmune
demyelinating disease, such as a diabetes complication or
leukodystrophy. In particular, adrenoleukodystrophy is a rare
inherited disorder that leads to progressive failure of the
adrenal gland, brain damage, and eventually death. In this
disease, the mutation of the ATP-binding cassette subfamily
D member 1 (ABCD1) gene leads to a reduction of beta
oxidation in peroxysomes with the accumulation of very long
chain fatty acids in the adrenal cortex and brain, causing
a progressive inflammatory demyelination. Because of its
crucial role in peroxisome proliferation and fatty oxidation,
PPARα was the prime target tested in a therapeutic approach.
However, no direct eﬀect of PPARα agonists could be seen
in modulating ABCD2, the closest relative of ABCD1, in the
brain [82]. It would still be interesting to test a PPARβ agonist
because of its combined role in fatty acid oxidation and in
oligodendrocyte maturation.
Alzheimer disease is a neurodegenerative disorder char-
acterized by cognitive and memory deterioration, pro-
gressive impairment of activities, and a multiplicity of
behavioral and psychological disturbances. While not fully
understood, the mechanism of the alteration includes an
extracellular accumulation of amyloidal plaque formed by
oligomerisation of the amyloidogenic peptide Aβ 1–42,
and the accumulation of the Tau protein responsible for
neurofibrillar degeneration. Interestingly, the noradrenalin
(NA) neurotransmitter protects neurons from inflammation
[83], via a mechanism that is partially PPARβ dependent. In
fact, in the model of primary cultures of rat cortical neurons
exposed to oligomeric amyloid beta, NA partially reduced
neuronal damage and toxicity, as assessed by a reduction in
the release of LDH. Interestingly, there was a concomitant
two fold induction of PPARβ mRNA and protein levels.
The NA neuroprotective eﬀects were partially blocked by
cotreatment with a PPARβ selective antagonist. Moreover,
the selective PPARβ agonist GW742 reduced LDH release
to the same extent as did the NA, suggesting that PPARβ
is the main mediator of NA action [84]. Nevertheless, high
concentrations of GW742 (50 μM) are required in order
to observe this eﬀect [85], and further in vivo studies are
required to evaluate the true potential of PPARβ agonists as
therapeutic tools for Alzheimer disease.
Finally, PPARβ agonist treatment could be beneficial in
another notorious neurodegenerative disorder: Parkinson
disease, characterized by the disappearance of the dopam-
inergique neurons with alteration of the nigrostriatal
pathways. Beside the classic occurrence of Parkinson disease,
whose etiology is mainly unknown, the synthetic opiate
1-methyl-4-phenyl-1,2,3,6-tetrahydrodropyridine (MPTP)
causes Parkinsonism in young drug-addicted individuals.
Iwashita et al. showed that an L-165041or GW501516
intracerebroventricular infusion 48 hours before the first
injection of MPTP protects against depletion of striatal
dopamine and its metabolites [63].
These diﬀerent studies highlight the need to characterize
and optimize some PPARβ agonists for their capacity to cross
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the blood-brain barrier in order to treat various acute and
chronic brain disorders.
7. CONCLUSION
This review highlights the few data available on PPARβ
activity in the brain. While sometimes highly speculative, it
underlines the good reasons to pursue dedicated research in
this domain. The brain is the second most lipid-enriched
tissue after adipose tissue. Products of fat metabolism, free-
fatty acids, ketone bodies, and glycerol dominate metabolic
pools in early development, as a consequence of the milk
diet. The high expression of the PPARβ lipid sensor during
brain maturation suggests that it is a key regulator of brain
metabolism during neurodevelopment. Moreover, PPARβ
anti-inflammatory and prosurvival activities may play a
prominent role in the acute phase of brain injury. In
addition, PPARβ prodiﬀerentiation activity, in particular
on oligodendrocyte lineage, is of potential benefit in the
treatment of neurodegenerative diseases. Therefore, in view
of its potentially wide therapeutical use, it appears crucial to
carry out in depth studies of the basic mechanism of PPARβ
activity, in order to understand the molecular network driven
by this receptor in the brain.
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